Table 2.

Effect of sacubitril/valsartan on glomerular filtration in patients with HF.

Study	Comparator	Patient population, ARNI/comparator (n)	Median duration of follow-up	Mean change from baseline in eGFR (mL/min per 1.73 m 2 per year)		p value
				ARNI	Comparator
PARAMOUNT, Voors et al. [4]	Valsartan	Patients with HFpEF, 149/152	36 weeks	−2.2a	−7.5a	NR
PARADIGM-HF (analysis of the CKD subgroup), Damman et al. [3]	Enalapril	HFrEF Patients with CKD, 1333/1412	48 months	−0.80	−1.55	< 0.001
PARADIGM-HF (analysis of the diabetes subgroup), Packer et al. [56]	Enalapril	HFrEF Patients with type 2 diabetes, 1907/1877	44 months	−1.70	−2.30	< 0.0001
PARAGON-HF (Prespecified analysis), Mc Causland et al. [55]	Valsartan	Patients with HFpEF, 2407/2389	48 months	−2.0	−2.7	< 0.001

Abbreviations: eGFR, estimated glomerular filtration rate; NR, not reported.

^aCalculated.